AstraZeneca is a leading global biopharmaceutical company, recognized for its innovation in oncology, respiratory, cardiovascular, and other therapeutic areas. In the highly competitive pharmaceutical industry, AstraZeneca faces direct competition and also collaborates with several major players. Understanding AstraZeneca’s competitive landscape is crucial for investors, healthcare professionals, and industry observers. Below, we outline AstraZeneca’s key competitors and peers, provide a comparative table, and offer head-to-head insights.
Key Competitors and Peers
- Amgen Inc. ($AMGN)
- Merck & Co., Inc. ($MRK)
- Pfizer Inc. ($PFE)
- Johnson & Johnson ($JNJ)
- Regeneron Pharmaceuticals, Inc. ($REGN)
- Bristol Myers Squibb Co. ($BMY)
- Eli Lilly & Co. ($LLY)
Competitive Peer Table
| Ticker | Company Name | Market Cap ($B) | Subsector |
|---|---|---|---|
| $AMGN | Amgen Inc. | 199.20 | Drug Manufacturers - General |
| $MRK | Merck & Co., Inc. | 286.28 | Drug Manufacturers - General |
| $PFE | Pfizer Inc. | 153.81 | Drug Manufacturers - General |
| $JNJ | Johnson & Johnson | 579.34 | Drug Manufacturers - General |
| $REGN | Regeneron Pharmaceuticals, Inc. | 77.97 | Biotechnology |
| $BMY | Bristol Myers Squibb Co. | 122.78 | Drug Manufacturers - General |
| $LLY | Eli Lilly & Co. | 884.72 | Drug Manufacturers - General |
AstraZeneca vs. Major Competitors
AstraZeneca vs. Amgen Inc. ($AMGN)
- Amgen and AstraZeneca are both major players in biologics and specialty pharmaceuticals.
- They collaborate directly on TEZSPIRE, with AstraZeneca leading global development and commercialization outside North America, while Amgen handles U.S. sales and manufacturing.
- They also compete directly: Amgen lists AstraZeneca’s FASENRA as a competitor to TEZSPIRE in the U.S. market.
AstraZeneca vs. Merck & Co., Inc. ($MRK)
- Merck and AstraZeneca have a strategic oncology collaboration, co-developing and co-commercializing Lynparza (olaparib) for multiple cancer types.
- AstraZeneca is the principal on Lynparza sales, while Merck is developing Lynparza with Keytruda for expanded indications.
- They also collaborate on Koselugo.
AstraZeneca vs. Regeneron Pharmaceuticals, Inc. ($REGN)
- Regeneron’s Dupixent competes with AstraZeneca/Amgen’s TEZSPIRE and AstraZeneca’s FASENRA in asthma and nasal polyps.
- Regeneron’s Libtayo competes with AstraZeneca’s Imfinzi in various cancer indications.
AstraZeneca vs. Pfizer Inc. ($PFE)
- No direct AstraZeneca-specific competitive positioning was cited in the provided filings.
- Both companies compete broadly across oncology, vaccines, and specialty care, but no explicit head-to-head product competition was highlighted.
AstraZeneca vs. Johnson & Johnson ($JNJ)
- No direct comparison was provided in the filings.
- Both companies have significant presence in oncology, immunology, and other therapeutic areas.
AstraZeneca vs. Bristol Myers Squibb Co. ($BMY)
- No explicit AstraZeneca-specific competitive positioning was cited.
- Both companies compete in oncology and immunology, with BMS’s Opdivo facing intense competition in immuno-oncology.
AstraZeneca vs. Eli Lilly & Co. ($LLY)
- No direct AstraZeneca-specific competitive positioning was cited.
- Both companies are global leaders with strong portfolios in oncology, immunology, and cardiometabolic health.
Conclusion
AstraZeneca operates in a dynamic and highly competitive environment, with both collaborative and competitive relationships with other pharmaceutical giants. Amgen, Merck, and Regeneron have the most explicit competitive and collaborative ties with AstraZeneca, especially in respiratory and oncology markets. Other peers like Pfizer, Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly are also significant competitors across multiple therapeutic areas, though direct product competition may vary. Understanding these relationships is key to assessing AstraZeneca’s strategic positioning and future growth prospects.